American Diabetes Association Urges U.S. Senate to Pass Stem Cell Research Legislation
Complete the form below to unlock access to ALL audio articles.
The American Diabetes Association has urged the U.S. Senate to take up and pass the "Stem Cell Research Enhancement Act of 2005" (H.R. 810/S.471), legislation that would accelerate stem cell research by easing existing restrictions and supporting research that uses embryonic stem cells.
It has almost been a year since the U.S. House of Representatives passed the stem cell legislation with clear, bipartisan support, but it has languished in the Senate since, despite the support of Senate Majority Leader Bill Frist. Public opinion polls show a strong majority of Americans support stem cell research.
The Association has been a strong supporter of the Stem Cell Research Enhancement Act because it would advance the search for better treatment and a cure for diabetes, one of the nation's most prevalent, debilitating and deadly diseases.
The Association applauds the bill's Senate sponsors -- Arlen Specter (R- PA), Tom Harkin (D-IA), Diane Feinstein (D-CA), Orrin Hatch (R-UT), Ted Kennedy (D-MA), and Gordon Smith (R-OR) -- for their continued leadership on the issue.
"Almost a year has passed since the U.S. House of Representatives took the bipartisan initiative to pass legislation to expand the number of stem cell lines that are eligible for federally funded research," said Lawrence T. Smith, Chair of the Board of the American Diabetes Association, and the father of a daughter who has type 1 diabetes.
"Americans with diabetes, and millions of Americans with other chronic and debilitating illnesses, shouldn't have to wait another year, much less another month or another day, for the Senate to finally pass this important legislation. We know the potential embryonic stem cell research has in the search for a cure, now we must ensure that researches have the opportunity to take advantage of this.”
Federal regulations that President Bush announced in 2001 have restricted the number of human embryonic stem cell lines available for federally-funded research, and attempted usage of those lines has demonstrated that the number of adequate lines is even smaller due to contamination.
Since 2001, scientists have discovered much better methods of deriving stem cell lines so that they do not face the same contamination issues. A significant expansion in the number of available lines is necessary in order to fully reap the medical rewards of stem cell research.
Stem cell research allows scientists to better explore how to control and direct stem cells so they can grow into other cells, such as insulin-producing beta cells found in the pancreas.
Creating new beta cells could mean a cure for type 1 diabetes as they would serve as a replenishable source of cells for islet cell transplantation. They could also provide a powerful tool for controlling type 2 diabetes.
